Teva in Q1: the legal provision fell, the payment schedule remains heavy

The main first-quarter analysis already framed Teva correctly: the innovative medicines engine is growing, the Emalex deal adds another pipeline asset, and the board has asked management to plan a possible share repurchase program. This continuation isolates the line that can be pushed aside when the discussion shifts to growth and capital allocation: the legal tail is still consuming cash, even as the accounting provision declines.

The prior legal-tail continuation showed that much of the risk had moved from a vague legal overhang into a visible payment schedule. The first quarter does not change that direction. It sharpens it. The total provision fell, but the opioid and DOJ PAP payment schedules remain heavy, third-party payer claims are not fully closed, and COPAXONE Europe still sits outside the simple cash chart.

The Provision Fell, The Expense Did Not Disappear

The reassuring number is the decline in the total provision for legal settlements and loss contingencies. At March 31, 2026, it stood at $4.680 billion, down from $4.753 billion at the end of 2025. That is a $73 million quarterly decline, and it is clearly better than another increase.

But that decline is not enough to treat the legal tail as a fading issue. First-quarter legal settlements and loss contingencies expense was $72 million, compared with $86 million in the prior-year quarter. The expense was still mainly tied to the opioid settlement provision, primarily the effect of the passage of time on the net present value of discounted payments. In other words, even without a major new legal shock, the old obligation continues to create expense.

That is the difference between accounting relief and cash relief. The provision declined by only 1.5%, while the company is still recording expense, still paying cash, and still carrying payment schedules that run deep into the end of the decade. Looking only at the balance-sheet decline gives an incomplete read.

The Cash Schedule Is A Multi-Year Drag

The cash frame here is all-in cash flexibility: how much cash remains after legal payments, CAPEX, debt service, acquisitions such as Emalex, and possibly a share repurchase. This is not an estimate of normalized maintenance cash generation before strategic uses. The distinction matters because legal payments are real cash uses that compete for the same pool of capital.

For the opioid settlements, the visible payment schedule for the coming years is now $379 million in 2026, of which $30 million had already been paid by March 31, $365 million in 2027, $416 million in 2028, $339 million in 2029 and $337 million in 2030. Additional payments remain beyond 2030, subject to adjustments.

Those amounts are not completely fixed. They can change based on payment timing, most-favored-nation clauses in prior settlements, and states’ elections to take the generic version of Narcan instead of cash. Still, the order of magnitude is clear: the visible opioid payment schedule alone totals $1.836 billion for 2026 through 2030.

The new first-quarter development is progress with third-party payers. In the first quarter, the company reached an agreement in principle with representatives of a third-party payer class. The agreement remains contingent on the company’s satisfaction with the level of participation by those payers. Until it is finalized, lawsuits brought by dozens of payers such as unions and welfare funds are expected to remain pending. The company also does not provide a reasonable upper end of the loss range for all remaining opioid-related cases.

Canada adds another partial step. In the first quarter, the company reached an agreement in principle to settle claims by one national consumer class brought in Ontario. It expects to memorialize the terms during 2026 and evaluate class participation before deciding whether to finalize the settlement. Other Canadian opioid actions remain in preliminary stages.

DOJ PAP Is Heavier At The Back End

The DOJ PAP settlement adds a different shape. The total amount is known: $425 million over 6 years, with no admission of wrongdoing. Of that amount, $19 million was paid in December 2024, $34 million was paid in January 2026, and the remaining schedule includes $49 million due in December 2026, $49 million in December 2027, $99 million in December 2028 and $175 million in December 2029.

The issue is not only the size of the amount. It is the timing. DOJ PAP does not decline in a straight line. The two heaviest years are 2028 and 2029, precisely when the opioid schedule also remains high. That is why the legal tail remains relevant to capital allocation even after the major settlements have been signed.

This table includes amounts already paid early in 2026: $30 million for opioids by the end of March and $34 million for DOJ PAP in January. That means the remaining 2026 amount after the end of the quarter is about $398 million, before ongoing legal fees and before any possible expansion of matters that are not yet fully resolved.

The larger visible number is $2.242 billion. That is the disclosed opioid and DOJ PAP cash payment schedule for 2026 through 2030, before opioid payments beyond 2030, before COPAXONE Europe, and before follow-on claims that cannot yet be fully priced. This is not a stress-case estimate. It is a cash schedule already embedded in the liability framework.

COPAXONE Europe Is Outside The Cash Chart

COPAXONE Europe is different from opioids and DOJ PAP. There is no annual cash schedule like the one above, so it should not be forced into the $2.242 billion figure. But it has not disappeared from the risk map.

The European Commission imposed a fine of 462.6 million euros, potentially subject to post-decision interest. The appeal before the General Court of the European Union remains pending. To cover the fine amount, the company has provided the Commission with surety-underwritten guarantees of 462.6 million euros, together with specified post-decision interest.

The less comfortable part is the surrounding claim layer. Generic competitors in Europe have brought similar antitrust claims in Germany and the Netherlands, and those cases have been stayed. Additional claims from generic competitors, payors or other private plaintiffs in Europe may also follow. COPAXONE Europe is therefore not a scheduled cash item, but an exposure that can change shape depending on the appeal and the behavior of private plaintiffs.

There are still open U.S. threads around COPAXONE as well. Some retailer and Mylan claims in the New Jersey cases were dismissed in April 2026, but renewed motions involving direct purchasers and indirect purchasers remain pending. Allegations linked to patient-assistance donations also continue to appear in securities litigation and derivative proceedings in Israel. That does not mean every thread becomes a material cash payment. It does mean the company is still managing a broad legal system around an older product that is no longer its main growth engine.

Capital Allocation Must Pass Through The Same Payment Schedule

The main analysis focused on whether growth in branded innovative products and the next pipeline layer can support both investment and balance-sheet improvement. The legal tail is a practical test of that question. In the first quarter, debt declined to $16.627 billion from $16.807 billion at the end of 2025, but the decrease was mainly due to exchange-rate fluctuations. That is not the same as debt reduction built from surplus cash generation.

The quarterly cash flow also requires caution. Operating cash flow was negative $40 million, better than negative $105 million in the prior-year quarter, but the company’s $188 million of free cash flow included $354 million of beneficial interest collected in exchange for securitized European receivables and $42 million of proceeds from sales of businesses and long-lived assets, offset by $168 million of capital investments. These are real cash sources, but they do not all come from the same place as core profitability.

Against that backdrop stands the Emalex deal. At closing, the company expects to pay $700 million in cash to Emalex’s existing shareholders, plus potential milestone payments of up to $200 million and royalties on global net sales after commercialization and subject to regulatory approval. The transaction is currently expected to close by the third quarter of 2026, subject to customary closing conditions and regulatory approvals.

The possible share repurchase adds another layer. No shares were repurchased in the first quarter, but in April 2026 the board instructed management to plan a program that may be implemented subject to applicable legal requirements and board approval. Beyond the cash outlay itself, there is a tax clause: under the agreement with the Israeli Tax Authorities, if the company pays dividends or repurchases equity interests in the future, it will pay an additional 5% to 7% of the amount of such dividends or repurchases in corporate taxes, up to a maximum tax payment of approximately $500 million.

That is why the legal tail is not merely a legal note. It sits in the same cash layer as debt, Emalex, pipeline investment and a possible repurchase. If core operating cash flow strengthens, the company can absorb all of these without changing direction. If cash quality remains too dependent on collection timing, securitization and disposals, the legal payment schedule will more quickly become a constraint on flexibility.

The Next Quarters Will Test Whether The Tail Is Really Shortening

The item that needs to move in the coming quarters is not only legal expense on the income statement. The total legal provision needs to start falling at a pace that looks like a real shortening of the tail, not just a small quarterly move. At the same time, opioid and DOJ PAP payments need to be absorbed without increasing reliance on balance-sheet tools.

The first trigger is finalization of the opioid TPP settlement and the level of participation. A broad final settlement could reduce one remaining uncertainty layer. A settlement that is too partial would leave more claims inside the system.

The second trigger is COPAXONE Europe. An appeal that leaves the picture unchanged would keep the guarantee and fine exposure in place. A development that reduces the exposure, or alternatively opens a wider private-claims path, would immediately change how the legal tail should be read.

The third trigger is the capital-allocation decision. Emalex already requires cash. A repurchase, if approved, would require more cash and could also bring an additional tax cost. That means 2026 free cash flow will not be judged only by the headline number, but by what remains after legal payments, CAPEX, debt, the acquisition and board decisions.

The implication is not that the company cannot afford the legal tail. It is that the tail is still large enough to compete for the same cash that is supposed to prove real deleveraging and fund the next growth chapter. The provision fell in the first quarter, but the cash test is far from over.